Heavy bleeding or urinary blockage needs urgent assessment

Seek Urgent Medical Care If

You pass thick blood or large clots and cannot urinate normally.
A catheter stops draining while the lower abdomen becomes painful or swollen.
You develop fever, chills, confusion, faintness or rapidly worsening weakness.
You have severe or increasing abdominal pain, swelling, vomiting or breathlessness after TURBT.

Urgent care may involve bladder drainage, clot removal, infection assessment, blood tests or imaging. Do not wait for a routine pathology appointment when urine is blocked or systemic illness is developing.

What Is TURBT?

“Transurethral” means through the urethra. “Resection” means controlled removal of tissue. A resectoscope carries a camera, irrigation and a cutting or coagulating element into the bladder. The surgeon inspects the lining, removes visible tumour and controls bleeding.

Tissue fragments or an en-bloc specimen are sent for histopathology. TURBT is therefore both diagnostic—confirming what the growth is and how deeply it extends—and therapeutic—removing visible disease from the bladder lining.

A visually complete TURBT is not automatically the end of treatment

Microscopic disease, flat carcinoma in situ, residual tumour or muscle invasion may not be apparent from the final camera view. The operation report and pathology must be reviewed together.

Why May TURBT Be Recommended?

Visible bladder tumour

A growth seen during cystoscopy or imaging usually requires tissue diagnosis and endoscopic removal when feasible.

Blood in urine

Painless haematuria can be the first sign of a bladder tumour, although stones, infection and other causes remain possible.

Suspicious bladder lining

Red, velvety or irregular areas may need targeted biopsy to assess for flat high-grade disease.

Positive urine cytology

Abnormal cells without an obvious tumour may prompt enhanced inspection, mapping biopsies, upper-tract assessment or prostatic-urethral sampling.

Recurrent tumour

A new growth detected during surveillance cystoscopy may require another resection for updated grade, stage and risk assessment.

Second-look resection

A planned repeat TURBT can clear residual disease and improve confidence in pathological staging.

How Is TURBT Different From Cystoscopy or Bladder Removal?

ProcedureMain purposeImportant distinction

Flexible cystoscopyInspect the bladder lining, often under local anaesthesia.Usually diagnoses a visible lesion but does not perform a full resection.

Bladder biopsySample a specific abnormal area.May not remove a larger visible tumour completely.

TURBTRemove visible tumour and obtain tissue for grade and stage.Preserves the bladder but may require repeat or additional treatment.

Radical bladder surgeryRemove the bladder for selected muscle-invasive or very high-risk disease.A major cancer operation planned after staging and multidisciplinary review.

What Happens Before TURBT?

Review of cystoscopy: Tumour site, size, number and appearance guide operative planning.
Upper-tract imaging: CT urography or another suitable study may assess the kidneys, ureters and disease beyond the bladder.
Urine assessment: Urinalysis, culture and cytology are used according to infection and cancer questions.
General assessment: Kidney function, blood count, anaesthetic fitness, allergies and previous urological procedures are reviewed.
Bleeding plan: Every regular medicine and bleeding or clotting condition is considered individually; interruption and restart decisions come from the treating team.
Consent: The discussion includes catheterisation, bleeding, perforation, incomplete resection, pathology uncertainty and possible further cancer treatment.

What Happens During TURBT?

StageWhat happensWhy it matters

Whole-bladder inspectionThe urethra, bladder lining, tumour and ureteric openings are examined under anaesthesia.Finds additional lesions and documents the surgical map.

Tumour descriptionNumber, size, location, shape and any concern for flat disease are recorded.Contributes to risk classification and future surveillance.

ResectionThe tumour is removed in controlled fractions or as a single specimen when feasible.Aims for complete visible removal while preserving interpretable tissue.

Base and muscle sampleThe tumour base is sampled to include detrusor muscle when oncologically important and safely possible.Helps determine whether cancer has invaded the bladder muscle.

HaemostasisBleeding points are coagulated and the bladder is reinspected.Reduces postoperative bleeding and confirms the final appearance.

Specimen labellingTumour, base and additional biopsies may be sent in separate labelled containers.Allows the pathologist to answer the stage and margin questions accurately.

Catheter decisionA bladder catheter, sometimes with irrigation, is placed when bleeding, resection depth or operative factors justify it.Maintains drainage and helps prevent clot retention.

Why Does Detrusor Muscle Matter?

Detrusor is the thick muscle layer of the bladder wall. Pathology must distinguish tumour limited to the lining or connective tissue from tumour that has entered this muscle. Muscle-invasive disease follows a very different staging and treatment pathway.

Absence of detrusor muscle from an important resection specimen can make staging less secure and is associated with a greater risk of residual disease or under-staging. It does not mean the operation was necessarily unsafe or unsuccessful: tiny low-grade surface tumours and primary carcinoma in situ are handled differently, and deep sampling can be hazardous at some sites.

Standard Resection and En-Bloc Resection

Resection in fractions

A loop removes the tumour piece by piece, followed by the base. This established technique accommodates many tumour sizes and locations.

En-bloc resection

A suitable lesion is removed as one specimen with its base. It can improve orientation and reduce tissue fragmentation but is not feasible for every tumour.

Electrical or laser energy may be used according to the tumour, equipment and surgeon. Excessive cautery can damage tissue architecture, so enough viable specimen must reach the pathologist.

Can Enhanced Imaging Be Used?

White-light cystoscopy is standard. Fluorescence-guided or narrow-band techniques can improve detection of selected small, multifocal or flat lesions when available. They complement—rather than replace—systematic inspection, adequate resection and pathology.

Positive urine cytology with no visible tumour may require enhanced inspection or mapping biopsies, plus assessment of the upper urinary tract and prostatic urethra.

Why Are Tumour Location and Size Important?

Lateral-wall tumours: Electrical stimulation can trigger a sudden thigh movement called an obturator reflex, increasing perforation risk.
Tumours near a ureteric opening: Resection requires care to preserve urine drainage from the kidney.
Dome or anterior-wall tumours: Angulation and wall thickness can make access and depth control more demanding.
Tumours in a diverticulum: The wall may lack normal muscle and perforation or staging uncertainty can be greater.
Large or numerous tumours: Complete removal may need more time, staged resection or referral depending on bleeding and perforation risk.

Why Might a Catheter and Irrigation Be Used?

A catheter drains urine while the resection surface begins to seal. Continuous bladder irrigation may be used when bleeding could form clots. Catheter need and duration depend on tumour burden, resection depth, bleeding, suspected perforation and the ability to urinate safely.

Some small uncomplicated resections need only brief catheterisation or none after recovery. A deep resection or bladder perforation can require longer drainage. The discharge plan should state when and where removal will occur and what to do if drainage stops.

What Is Immediate Bladder-Directed Treatment?

For selected non-muscle-invasive tumours, the team may place a single dose of cancer treatment directly into the bladder soon after TURBT to reduce implantation and early recurrence. This is a local treatment decision—not a routine step for everyone.

It is generally withheld when perforation is suspected, resection is extensive, bleeding is heavy, irrigation is required or another safety concern exists. Later bladder-directed courses depend on the final risk group and are planned separately.

What Should I Expect After TURBT?

Burning, urgency, frequency and pink or red urine can occur during early healing.
Small clots or a temporary return of bleeding can occur when the resection surface sheds healing material.
Hospital stay depends on anaesthesia, bleeding, catheter status, tumour burden and other medical conditions.
Return to driving, work, travel, lifting and sexual activity should follow the individualized discharge advice.
Any interrupted regular treatment should be restarted only according to the written medical plan.

After TURBT

Contact the Treating Team Urgently If

Bleeding becomes thick, persistent or associated with large clots.
You cannot pass urine, or a catheter stops draining while discomfort increases.
You develop fever, chills, confusion, faintness or feel significantly unwell.
Abdominal or pelvic pain and swelling become severe or progressively worse.
Urine output falls markedly or you develop persistent vomiting or breathlessness.

Possible Risks and Limitations

Bleeding and clot retention

Bleeding may require irrigation, catheter drainage, clot evacuation, transfusion or repeat haemostasis.

Urinary infection

Instrumentation and catheterisation can lead to bladder infection or, less commonly, severe systemic infection.

Bladder perforation

A deep resection can create a hole in the bladder wall. Many heal with catheter drainage; larger or intraperitoneal injuries may need repair.

Incomplete resection

Large, numerous, awkwardly placed or deeply invasive tumours may not be safely removable in one session.

Ureteric injury

Resection near a ureteric opening can cause swelling, scarring or impaired drainage and may require additional management.

Urethral injury or stricture

Passage of instruments can injure or later narrow the urethra.

Obturator reflex

Sudden leg movement during lateral-wall resection can increase perforation risk despite anaesthetic precautions.

Recurrence or progression

TURBT removes visible disease but cannot guarantee that bladder cancer will not recur or become more aggressive.

What Does the Pathology Report Tell Us?

Histological typeUsually urothelial carcinoma, although less common tumour types and variants exist.

Low grade / high gradeDescribes how abnormal and biologically aggressive the cells appear.

TaPapillary tumour confined to the bladder lining without invasion beneath it.

Tis / CISFlat high-grade carcinoma in situ within the lining; it can be difficult to see and carries meaningful progression risk.

T1Tumour has invaded connective tissue beneath the lining but not proven bladder muscle.

T2Tumour has invaded detrusor muscle and requires a muscle-invasive cancer pathway.

Detrusor muscle presentThe pathologist received bladder muscle and can assess it for invasion.

Lymphovascular invasionTumour cells are seen in lymphatic or blood vessels, an adverse risk feature.

Variant histologyA less common growth pattern that may alter risk assessment and treatment.

Cautery artefactHeat change makes part of the tissue harder to interpret.

Non-Muscle-Invasive and Muscle-Invasive Disease

Non-muscle-invasive bladder cancer

Ta, T1 and carcinoma in situ have not been shown to enter detrusor muscle. Management is risk-stratified and can include surveillance, repeat TURBT, bladder-directed treatment or selected early radical surgery.

Muscle-invasive bladder cancer

T2 or deeper disease requires staging scans and multidisciplinary planning. TURBT provides diagnosis and may relieve bleeding, but is not usually definitive treatment by itself.

Why Might I Need a Second TURBT?

The initial resection was incomplete or completeness is uncertain.
The tumour is staged as T1.
Detrusor muscle is absent from an important specimen, except in selected low-grade Ta tumours and primary carcinoma in situ.
High-risk pathological or operative features require confirmation and clearance.

When indicated, a second TURBT is commonly planned within approximately two to six weeks and includes resection of the original tumour site. Timing remains individualized according to healing, bleeding, infection, pathology and referral arrangements.

What Happens After the Pathology Result?

FindingTypical next discussionWhy

Low-risk surface tumourRisk-appropriate cystoscopic surveillance, with bladder-directed treatment when indicated.Balances recurrence prevention with treatment burden.

Intermediate-risk diseaseSurveillance plus a tailored course of bladder-directed treatment.Recurrence risk is higher or more persistent.

High-risk non-muscle-invasive diseaseSecond TURBT when indicated, intensive bladder-directed treatment and discussion of radical surgery in selected cases.Progression risk can be substantial despite the word “non-muscle-invasive.”

Muscle-invasive diseaseStaging and multidisciplinary consideration of radical surgery, combined bladder-preserving treatment or systemic therapy.TURBT alone does not address disease within or beyond the bladder muscle.

Benign or uncertain tissueCorrelation with cystoscopy, imaging and operative findings; pathology review or repeat sampling when discordant.A benign fragment must still explain the visible lesion.

What Does Successful TURBT Mean?

A high-quality TURBT aims to remove all safely resectable visible tumour, provide interpretable tissue with adequate depth, document the complete bladder map and avoid preventable complications. Success also means that the pathology reaches the treating team promptly and leads to the correct next stage of care.

Bladder cancer can recur elsewhere in the lining even after an excellent resection. Surveillance cystoscopy is therefore part of treatment, not evidence that the first operation failed.

Common Operation and Report Terms

Papillary tumourA frond-like growth projecting into the bladder cavity.

Broad-based / sessile tumourA flatter solid-looking lesion with a wider attachment to the bladder wall.

MultifocalMore than one tumour is present in separate bladder sites.

Macroscopic complete resectionNo visible tumour remains at the end of the operation; microscopic disease can still exist.

Tumour baseTissue beneath the visible growth, sampled to assess depth.

Ureteric orificeThe opening where a ureter drains urine into the bladder.

Bladder diverticulumA pouch in the bladder wall that may have thin or absent detrusor muscle.

Re-TURBT / second lookA planned repeat resection to clear residual tumour or improve staging accuracy.

Common Myths

Myth “TURBT is only a biopsy.”

Fact It provides diagnostic tissue and aims to remove all safely resectable visible tumour.

Myth “No visible tumour means the cancer is cured.”

Fact Pathology, microscopic disease and future recurrence risk still determine treatment.

Myth “TURBT removes the bladder.”

Fact It removes tumour from inside while leaving the bladder in place.

Myth “Missing muscle means there is definitely no muscle invasion.”

Fact If muscle was not sampled, invasion may remain uncertain and repeat resection can be necessary.

Myth “A second TURBT means the first surgeon failed.”

Fact Second-look resection is an evidence-based staging and clearance step for defined situations.

Myth “Surveillance is optional after complete removal.”

Fact Bladder tumours can recur at another site, so risk-appropriate cystoscopy remains essential.

Frequently Asked Questions

What does TURBT stand for?

TURBT means transurethral resection of bladder tumour—endoscopic removal of a bladder growth through the urethra.

Is there a cut on the abdomen?

Not routinely. The resectoscope passes through the natural urinary passage. A separate operation is needed only for an unusual complication or another planned procedure.

Is TURBT a biopsy or treatment?

Both. It obtains tissue for diagnosis and staging while aiming to remove all safely resectable visible tumour.

Does a bladder tumour always mean cancer?

No. Pathology establishes the diagnosis. However, a suspicious visible tumour must be treated as potentially malignant until tissue proves otherwise.

Why is bladder muscle included in the specimen?

Detrusor muscle lets the pathologist assess whether the tumour has reached the muscular bladder wall, which changes staging and treatment.

Will I need a catheter?

Many patients need temporary catheter drainage, particularly after a larger or deeper resection or when bleeding requires irrigation. Some small uncomplicated resections do not require prolonged catheterisation.

Why might the catheter need irrigation?

Irrigation prevents blood from forming obstructing clots and allows staff to monitor whether bleeding is settling.

Can bladder treatment be given immediately?

Selected patients receive a local bladder treatment after resection. It is withheld if perforation, heavy bleeding, extensive resection or another safety concern exists.

Why might I need another TURBT?

A second resection may be needed after incomplete removal, T1 disease, missing detrusor muscle or other high-risk findings.

What is the difference between Ta, T1 and T2?

Ta is confined to the lining, T1 enters connective tissue beneath it, and T2 invades detrusor muscle.

What is carcinoma in situ?

Carcinoma in situ is a flat high-grade cancer within the bladder lining. It can be subtle or invisible and has meaningful progression risk.

Can TURBT cure bladder cancer?

It may be the principal physical treatment for selected low-risk non-muscle-invasive disease, but recurrence surveillance and additional treatment depend on pathology and risk.

What happens if muscle-invasive cancer is found?

Staging scans and multidisciplinary specialist review are needed. TURBT supplies the diagnosis but usually is not definitive treatment by itself.

Can bleeding return after I go home?

Yes. Healing tissue can bleed again. Thick bleeding, large clots, inability to urinate or worsening illness needs urgent assessment.

When is higher-centre referral appropriate?

Muscle-invasive, very high-risk, extensive, difficult-site or incompletely resected tumours and patients needing radical or combined cancer treatment should enter an appropriate specialist pathway.

TURBT